Internet Archive Scholar

mRNA-based vaccine candidate COReNAPCIN® induces robust humoral and cellular immunity in mice and non-human primates [article]

Reza Alimohammadi, Meysam Porgoo, Mohamad Eftekhary, Seyed Hossein Kiaie, Ehsan Ansari Dezfouli, Maryam Dehghani, Kaveh Nasrollah, Talieh Malekshahab, Maryam Heidari, Sedigheh Pouya, Masoumeh Alimohammadi, Dorsa Sattari Khavas (+36 others)
2022 bioRxiv   pre-print

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.5 MB)
https://web.archive.org/web/20220526224645/https://www.biorxiv.org/content/biorxiv/early/2022/03/07/2022.03.05.483092.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN® ; a vaccine
more » ... andidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2×108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.
doi:10.1101/2022.03.05.483092 fatcat:cg6yfiyz7bgxpfmgpmtg3ccopu
Citation

Reza Alimohammadi, Meysam Porgoo, Mohamad Eftekhary, Seyed Hossein Kiaie, Ehsan Ansari Dezfouli, Maryam Dehghani, Kaveh Nasrollah, Talieh Malekshahab, Maryam Heidari, Sedigheh Pouya, Masoumeh Alimohammadi, Dorsa Sattari Khavas, Mohammad Sadra Modaresi, Mohammad Hossein Ghasemi, Hamed Ramyar, Fatemeh Mohammadipour, Fateme Hamzelouei, Ahmadreza Mofayezi, Seyed Saeed Mottaghi, Amirhosein Rahmati, Mohsen Razzaznian, Vista Tirandazi, Fatemeh Borzouee, Hossein Sadeghi, Melika Haji Mohammadi, Leila Rastegar, Seyed Milad Safar Sajadi, Hossein Ehsanbakhsh, Hamed Bazmbar, Maedeh Shams Nouraee, Pouya Pazooki, Mina Pahlevan Neshan, Khadijeh Alishah, Fateme Nasiri, Neda Mokhberian, Seyedeh Shima Mohammadi, Shima Akar, Hamidreza Niknam, Marzyie Azizi, Mohammad Ajoudanian, Mohammad Hossein Moteallehi-Ardakani, Seyed Ali Mousavi Shaegh, Reihaneh Ramezani, Vahid Salimi, Reza Moazzami, Seyed Mahmoud Hashemi, Somaye Dehghanizadeh, Vahid Khoddami. "mRNA-based vaccine candidate COReNAPCIN® induces robust humoral and cellular immunity in mice and non-human primates." bioRxiv (2022)